Impact of CDC Panchakarma Protocol With Prameha Diet Box on Glycemic Control and Reduction of Antidiabetic Medications in Type 2

Background: Type 2 Diabetes Mellitus (T2DM) imposes an escalating global burden requiring lifelong pharmacological management with cumulative adverse effects. Integrated Ayurvedic management combining Panchakarma bio-purification therapy, calorie-restricted diet, and herbal medications offers a multi-modal therapeutic alternative addressing the underlying metabolic dysfunction of T2DM. Objective: To evaluate the effects of the CDC Panchakarma Protocol with the Prameha Diet Box on glycemic control, anthropometric parameters, and allopathic medication requirements in T2DM patients. Methods: Retrospective observational study of 34 T2DM patients (24 male, 10 female; mean age 42.3±9.9 years) treated at Talegaon Ayurvedic clinic between April 2025 and March 2026. Patients received BMI-stratified Panchakarma (CDC-SP: BMI ≥23 kg/m², n=23; CDC-KP: BMI <23 kg/m², n=5), the 800-kcal Prameha Diet Box, and individualized oral herbal medications. Paired t-tests compared baseline and post-treatment clinical parameters. Results: Statistically significant improvements were observed in HbA1c (8.41±2.20% → 7.53±1.46%; Δ −0.88%; p=0.008), RBS (197.5±64.8 → 162.6±67.4 mg/dL; Δ −34.9 mg/dL; p=0.001), body weight (Δ −2.90 kg; p<0.001), BMI (Δ −1.14 kg/m²; p<0.001), and abdominal girth (Δ −4.15 cm; p<0.001). Post-treatment, 41.2% of patients achieved HbA1c <7.0%. Critically, 67.6% of patients reduced their allopathic medication dosage and 38.2% discontinued all allopathic medications entirely. Conclusion: The CDC Panchakarma Protocol demonstrated significant improvements in glycemic control, body composition, and allopathic medication dependency in T2DM. The magnitude of medication de-escalation achieved is clinically remarkable. Prospective randomized controlled trials are warranted to confirm these findings.